Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pf-07934040
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-07934040 is an orally available, investigational small molecule inhibitor targeting the KRAS protein. It is being developed by Pfizer for the treatment of advanced solid tumors harboring mutations in the KRAS gene, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). As a pan-KRAS inhibitor, it aims to block aberrant signaling caused by various oncogenic KRAS mutations that drive tumor growth. The drug is currently in Phase 1 clinical trials as both monotherapy and in combination with other targeted agents[5][7][9].
- Other names
- PF 07934040PF07934040PF-07934040PF4040PF-4040PF 4040
02
Targets
Beyond the preview
Go deeper on pf-07934040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pf-07934040.